Northland Securities set a $8.00 price objective on vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Wednesday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages also recently weighed in on VTVT. HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of vTv Therapeutics in a report on Friday, August 16th. Zacks Investment Research downgraded vTv Therapeutics from a buy rating to a hold rating in a report on Wednesday, August 21st. Finally, ValuEngine downgraded vTv Therapeutics from a hold rating to a sell rating in a report on Wednesday, September 4th.
NASDAQ:VTVT traded down $0.02 during trading hours on Wednesday, hitting $1.57. 714,332 shares of the company were exchanged, compared to its average volume of 825,767. The stock has a market capitalization of $94.04 million, a price-to-earnings ratio of -2.28 and a beta of -3.64. vTv Therapeutics has a one year low of $0.75 and a one year high of $6.09. The company has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $1.53.
vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The company had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.63 million. On average, research analysts anticipate that vTv Therapeutics will post -0.53 EPS for the current year.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 50,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $1.38 per share, for a total transaction of $69,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Ronald O. Perelman purchased 606,061 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were acquired at an average price of $1.65 per share, with a total value of $1,000,000.65. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 811,061 shares of company stock valued at $1,273,751. Company insiders own 1.70% of the company’s stock.
A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. grew its holdings in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,031 shares of the biotechnology company’s stock after acquiring an additional 13,305 shares during the period. BlackRock Inc. owned 0.12% of vTv Therapeutics worth $93,000 as of its most recent SEC filing. 1.64% of the stock is currently owned by hedge funds and other institutional investors.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.